Sustained disease remission in multiple sclerosis after autologous haematopoietic stem cell transplantation. The Italian experience

This is the author's manuscript

Original Citation:

Availability:
This version is available http://hdl.handle.net/2318/1700688 since 2019-05-02T17:35:54Z

Terms of use:
Open Access
Anyone can freely access the full text of works made available as "Open Access". Works made available under a Creative Commons license can be used according to the terms and conditions of said license. Use of all other works requires consent of the right holder (author or publisher) if not exempted from copyright protection by the applicable law.

(Article begins on next page)
This is the author's final version of the contribution published as:

Sustained disease remission in multiple sclerosis after autologous haematopoietic stem cell transplantation. The Italian experience. Boffa G; Sormani MP; Repice AM; Curro D; Capobianco M; Gualandi F; Lo Re M; De Gobbi M; Innocenti C; Capello E; Mariottini A; Forci B; Uccelli A; Barilaro A; Cottone S; Bertolotto A; Saccardi R; Mancardi GL; Massacesi L. MULTIPLE SCLEROSIS JOURNAL. Volume: 23 . Pages: 307-308. Supplement: 3 Meeting Abstract: P652. Published: OCT 2017

The publisher's version is available at:
giacomo.boffa.sustained.disease.remission.in.multiple.sclerosis.after.html]

When citing, please refer to the published version.

Link to this full text:
[inserire l'handle completa, preceduta da http://hdl.handle.net/]
Sustained disease remission in multiple sclerosis after autologous haematopoietic stem cell transplantation. The Italian experience

Boffa G, Sormani MP; Repice AM; Curro D; Capobianco M; Gualandi F; Lo Re M; De Gobbi M; Innocenti C; Capello E; Mariotti A; Forci B; Uccelli A; Barilaro A; Cottone S; Bertolotto A; Saccardi R; Mancardi GL; Massacesi L

Abstract: P652

Type: Poster

Abstract Category: Therapy - disease modifying - 26
Immunomodulation/Immunosuppression

Background: Despite the advent of new highly-active therapies for multiple sclerosis (MS), long-term disease remission remains elusive and only a small percentage of patients achieves the so-called no evidence of disease activity (NEDA) status. This is particularly relevant for patients with aggressive MS with suboptimal response to conventional treatment. Against this scenario, autologous haematopoietic stem cell transplantation (AHSCT) has recently demonstrated the potential to maintain long-term disease remission in aggressive MS patients.

Objective: To evaluate the long-term outcomes of a large multicenter cohort of aggressive MS patients treated with AHSCT.

Methods: Data were obtained in a multicenter, observational, retrospective cohort study including patients treated with AHSCT with the same conditioning regimens in Italy from 1996 to 2016. EDSS progression was defined as 1 EDSS point increase (0.5 if baseline EDSS >= 5.5) confirmed at 6 months. Demographic, disease-related and treatment-related data and reports of adverse events were collected.

Results: 122 consecutive MS patients were included, with a median follow-up of 4.7 years (range, 0.5-17 years). 59% of patients had relapsing-remitting (RR) MS. The median EDSS score was 5 (range 1-8.5) 1 year before AHSCT and 6 (range 1-9) at AHSCT. One death (0.8%) was reported within 100 days of transplant. Stem cell were mobilized with cyclophosphamide and G-CSF; 102 patients (84%) were conditioned with carmustine-cytarabine-etoposide-melphalan (BEAM) plus anti-thymocyte globulin (ATG) whilst 20 patients (16%) with cyclophosphamide plus ATG. Only patients who underwent the BEAM protocol were included in the long-term analysis. The 5-year probability of progression-free survival were 91% for RRMS and 62% for SPMS respectively (p< 0.001). NEDA status (defined as no relapses, no EDSS progression and no MRI activity) at 5 year was maintained by 72% of RRMS patients and by 55% of SPMS patients (p=0.07).

Conclusion: Our data demonstrate that AHSCT is reasonably safe and extremely effective for inducing long-term disease remission in aggressive MS patients.

Disclosure: GB, DC, EC, FG, MC, MLR, MDG, CI, AM, BC, AB have nothing to disclose.

MPS: MPS received consulting fees from TEVA, Biogen, Merck Serono, Genzyme, Roche, GeNeuro, Novartis, Medday.

GLM: GLM has received honoraria for lecturing, travel expenses for attending meetings, and financial support for research from Bayer Schering, Biogen Idec, Sanofi Aventis, Teva, Genzyme, and Merck Serono Pharmaceuticals.
AU: AU has received consulting honoraria and/or speaker fees and basic science study grants from Biogen Idec; consulting honoraria and/or speaker fees from Genzyme, Roche, Sanofi Aventis, and Teva; consulting honoraria and/or speaker fees and a basic science study grant from Novartis; consulting honoraria and/or speaker fees and a basic science study grant from Merck Serono.

AB: AB has received honoraria for serving in the scientific advisory boards of Biogen, Merck, Mylan, Sanofi-Genzyme, and received speaker honoraria from Biogen, Genzyme, Novartis, TEVA; his institution has received grant support from Almirall, Bayer, Biogen, Genzyme, Merck, Novartis, TEVA, from the Italian Multiple Sclerosis Society, Fondazione Associazione Ricerca Biomedica ONLUS and San Luigi ONLUS

RS: RS has received honoraria for lecturing and consulting da Sanofi, Jazz pharmaceutical e Biosafe.

SC: SC has received honoraria for serving in the scientific advisory boards of Biogen, Merck, Teva, Bayer

LM: LM has received honoraria for symposia, advisory boards, preceptorship, consultations from: Biogen, Teva, Merk-Serono, Novartis, Genzyme, Roche, Mylan and educational grants for participation in international meetings from Biogen, Teva, Merk-Serono, Novartis, Genzyme, Roche

AMR: AMR has received consulting fees from Merck-Serono, Biogen, Novartis, Sanofi-Genzyme and funding for travel from Teva, Biogen, Novartis

This full text was downloaded from iris-Aperto: https://iris.unito.it/